Compare LBRDK & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRDK | LQDA |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.5B |
| IPO Year | 2014 | 2020 |
| Metric | LBRDK | LQDA |
|---|---|---|
| Price | $36.77 | $71.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | ★ 2.7M | 1.5M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.91 | ★ 51.81 |
| EPS | ★ 4.55 | 1.26 |
| Revenue | $22,256,000.00 | ★ $158,320,000.00 |
| Revenue This Year | N/A | $278.87 |
| Revenue Next Year | $109.28 | $57.13 |
| P/E Ratio | ★ $7.95 | $55.94 |
| Revenue Growth | 70.00 | ★ 1031.18 |
| 52 Week Low | $26.25 | $21.15 |
| 52 Week High | $65.73 | $93.61 |
| Indicator | LBRDK | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 56.88 | 39.05 |
| Support Level | $29.37 | $70.28 |
| Resistance Level | $39.60 | $92.35 |
| Average True Range (ATR) | 1.62 | 4.56 |
| MACD | -0.01 | -1.61 |
| Stochastic Oscillator | 71.46 | 12.48 |
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.